Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors

摘要

Abstract Novel rhodesain inhibitors were developed by combining an enantiomerically pure 3-bromoisoxazoline warhead with a 1,4-benzodiazepine scaffold as specific recognition moiety. All compounds were proven to inhibit rhodesain with K_i values in the low-micromolar range. Their activity towards rhodesain was found to be coupled to an in vitro antitrypanosomal activity, with IC₅₀ values ranging from the mid-micromolar to a low-micromolar value for the most active rhodesain inhibitor (R,S,S)- 3 . All compounds showed a good selectivity against the target enzyme since all of them were proven to be poor inhibitors of human cathepsin L.